ATyr Pharma Raised to Buy From Hold by Freedom Broker
Freedom Broker has upgraded its rating for ATyr Pharma from Hold to Buy. This change in rating suggests a more positive outlook on the company's stock from the brokerage firm.
aTyr Pharma stock (US53227K1025): clinical pipeline update keeps biotech in focus
aTyr Pharma, a clinical-stage biotech focused on immune-modulating protein therapeutics, remains a key focus for investors due to recent pipeline and financing updates. The company is advancing its lead candidate for interstitial lung diseases through mid-stage trials, with its business model highly dependent on clinical trial outcomes and capital market conditions. For US investors, the stock offers exposure to high-risk, early-stage biopharmaceutical innovation on the Nasdaq, with significant upside potential but also considerable scientific, regulatory, and financial uncertainties.
Freedom Capital Markets Initiates ATyr Pharma(ATYR.US) With Buy Rating, Announces Target Price $3.5
Freedom Capital Markets has initiated coverage of ATyr Pharma (ATYR.US) with a 'Buy' rating. The firm has set a target price of $3.5 for the biopharmaceutical company's stock. This initiation suggests a positive outlook on ATyr Pharma's future performance by Freedom Capital Markets.
ATYR Upgraded by Freedom Broker -- Price Target Raised to $3.50
ATyr Pharma Inc. (ATYR) has been upgraded from a 'Hold' to a 'Buy' rating by Freedom Broker analyst Ilya Zubkov, with its price target significantly raised from $1.00 to $3.50. Despite this positive analyst outlook, GuruFocus indicates that ATYR is currently 14.4% overvalued with a GF Value™ of $0.47 against its trading price of $0.54, and has a low GF Score™ of 24/100, reflecting challenges in financial performance and profitability. Investors are advised to consider the mixed signals, including the optimism from analysts against the company's valuation and financial strength metrics.
aTyr Pharma upgraded to Buy from Hold at Freedom Broker
Freedom Broker upgraded aTyr Pharma (ATYR) to a Buy rating from Hold, increasing its price target to $3.50 from $1. This upgrade follows the FDA's confirmation for continuing efzofitimod development in chronic symptomatic pulmonary sarcoidosis, removing some uncertainty. The firm highlighted the drug's ultra-orphan profile and potential in orphan diseases as key reasons for the improved rating.
Atyr plans new global clinical trial of efzofitimod in pulmonary sarcoidosis
Atyr Pharma plans to launch a new global Phase 3 clinical trial (C-006) for its investigational therapy, efzofitimod, to treat pulmonary sarcoidosis patients with a restrictive lung profile. This decision follows discussions with the FDA, which will emphasize forced vital capacity (FVC) as the primary outcome. The previous EFZO-FIT trial failed its main goal but showed benefits in quality of life and corticosteroid reduction.
Number of shareholders of aTyr Pharma, Inc. – LS:A2PM86
The article provides a brief mention of the number of shareholders for aTyr Pharma, Inc. (LS:A2PM86). The content is primarily structural navigation and copyright information for TradingView and related financial data services, with little substantive detail about the shareholder count itself. It appears to be a stub or a placeholder for financial data that is not explicitly presented in the provided text.
Number of shareholders of aTyr Pharma, Inc. – NASDAQ:ATYR
This article provides details on the number of shareholders for aTyr Pharma, Inc. (NASDAQ: ATYR) as listed on TradingView. It appears to be a financial data page rather than an analytical piece, offering numerical values for periods with changes and percentage changes.
Atyr Pharma: Q1 Earnings Snapshot
Atyr Pharma Inc. (ATYR) reported a first-quarter loss of $10.8 million, or 11 cents per share. The company's shares closed at 56 cents, a significant drop from $3.03 a year ago. This financial data was generated by Automated Insights using Zacks Investment Research.
[10-Q] aTYR PHARMA INC Quarterly Earnings Report
aTyr Pharma, Inc. has filed its Quarterly Earnings Report (Form 10-Q) for the period ended March 31, 2026. The clinical-stage biotechnology company reported a consolidated net loss of $10.8 million for the three months ended March 31, 2026, and highlighted its ongoing efforts in developing efzofitimod for interstitial lung disease, including plans for a new Phase 3 study in pulmonary sarcoidosis. The report also notes the termination of its collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd., effective August 10, 2026, which will return global rights for efzofitimod to aTyr Pharma.
aTyr Pharma Inc options imply 30.5% move in share price post-earnings
Options trading for aTyr Pharma Inc. (ATYR) suggests a potential 30.5% shift in its share price following its upcoming earnings release. While current options activity indicates a significant move, the median price movement for the company over the last eight quarters has been 5.9%. Calls are notably outnumbering puts by 142:1 in pre-earnings options volume.
Atyr Pharma: Q1 Earnings Snapshot
Atyr Pharma Inc. (ATYR) reported a first-quarter loss of $10.8 million, translating to 11 cents per share. The company's shares closed at 56 cents, a significant decrease from $3.03 a year ago. This financial summary was compiled using data from Zacks Investment Research.
aTyr Pharma (NASDAQ: ATYR) details Q1 2026 loss and Phase 3 plan
aTyr Pharma reported a net loss of $10.8 million for Q1 2026, an improvement from $14.9 million in Q1 2025. The company plans to submit an Investigational New Drug (IND) application in June 2026 for a global Phase 3 study of efzofitimod in pulmonary sarcoidosis and is on track to complete enrollment for its Phase 2 EFZO-CONNECT SSc-ILD trial in the first half of 2026. aTyr ended the quarter with $68.3 million in cash, cash equivalents, restricted cash, and investments.
aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update
aTyr Pharma (NASDAQ: ATYR) announced its first quarter 2026 results and provided a corporate update, including a clear path forward for efzofitimod in pulmonary sarcoidosis following a Type C meeting with the FDA. The company plans to submit an IND in June 2026 for a Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis, using FVC as the primary endpoint. Additionally, aTyr is on track to complete enrollment in the Phase 2 EFZO-CONNECT™ study for SSc-ILD in the first half of 2026 and ended the quarter with $68.3 million in cash and investments.
Biotech plans global lung disease trial after FDA talks, holds $68M cash
aTyr Pharma reported Q1 2026 results, ending March 31, 2026, with $68.3 million in cash. The company plans to file an IND in June 2026 for a new global Phase 3 trial of efzofitimod in pulmonary sarcoidosis, following positive FDA Type C meeting feedback. Additionally, aTyr is on track to complete enrollment for its Phase 2 EFZO-CONNECT SSc-ILD study in the first half of 2026 and released promising preclinical data for ATYR0101.
Atyr Pharma: Q1 Earnings Snapshot
Atyr Pharma Inc. (ATYR) reported a loss of $10.8 million in its first quarter, amounting to 11 cents per share. The company's stock closed at 56 cents, a significant drop from $3.03 a year ago. This financial summary was generated using data from Zacks Investment Research.
aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update
aTyr Pharma announced its first quarter 2026 results and provided a corporate update, highlighting plans to continue developing efzofitimod for pulmonary sarcoidosis. The company will submit an IND in June 2026 for a Phase 3 study in chronic, symptomatic pulmonary sarcoidosis patients with restrictive lung disease, using FVC as the primary endpoint. They also reported $68.3 million in cash and investments at the end of Q1 2026.
12 Health Care Stocks Moving In Thursday's Intraday Session
This article lists several healthcare stocks that experienced significant intraday movement on Thursday. It details both gainers like Quantum Cyber and Innate Pharma, with some rising over 70%, and losers such as MDxHealth and Regenxbio, which saw declines of over 37%, often correlating with recent earnings reports.
aTyr Pharma to Participate in Upcoming Investor Conferences
aTyr Pharma, Inc. (Nasdaq: ATYR) announced its participation in two upcoming investor conferences: the RBC Capital Markets Global Healthcare Conference on May 20, 2026, and the Jefferies Global Healthcare Conference on June 4, 2026. President and CEO Sanjay S. Shukla will speak at the Jefferies event, which will also feature one-on-one meetings with investors and a webcast. The company, a clinical-stage biotechnology firm, focuses on developing medicines from its proprietary tRNA synthetase platform.
[Form 4] aTYR PHARMA INC Insider Trading Activity
aTyr Pharma director Timothy Coughlin has been granted a compensatory stock option to acquire 50,000 shares of common stock at an exercise price of $0.95 per share, expiring May 11, 2036. The option vests in full on the earlier of May 11, 2027, or the company's 2027 Annual Meeting of Stockholders, provided Coughlin continues his board service. This transaction increases his direct holdings of stock options to 50,000 shares.
Biotech developing lung disease drug plans Jefferies fireside chat
aTyr Pharma (Nasdaq: ATYR) announced its participation in two upcoming investor conferences: the RBC Capital Markets Global Healthcare Conference on May 20, 2026, and the Jefferies Global Healthcare Conference on June 4, 2026. At Jefferies, President and CEO Sanjay S. Shukla will conduct a fireside chat, which will be webcast. The company is clinical-stage, specializing in therapies for fibrosis and inflammation, with their lead candidate, efzofitimod, targeting interstitial lung disease.
Director Jane Gross (ATYR) awarded 50,000 aTyr Pharma stock options at $0.95
aTyr Pharma director Jane A. Gross was granted 50,000 stock options at an exercise price of $0.95 per share as part of her non-employee director compensation. These options will vest in full on the earlier of May 11, 2027, or the company’s 2027 Annual Meeting of Stockholders, provided she continues her service on the Board. This transaction, detailed in a Form 4 SEC filing, increases her direct holdings to 50,000 stock options.
12 Health Care Stocks Moving In Wednesday's Intraday Session
This article identifies 12 healthcare stocks that experienced significant price movements during Wednesday's intraday trading session. It lists both gainers and losers, including companies like Quantum Cyber, Whitehawk Therapeutics, Replimune Group, and MaxCyte among the gainers, and WORK Medical Tech Gr, Reviva Pharma, and TriSalus Life Sciences among the decliners. The movements are often attributed to recent Q1 earnings reports.
aTyr Pharma(ATYR) Stock Options Chain | Quotes & News
This article provides access to the stock options chain, quotes, and news for aTyr Pharma (ATYR). It is a short, placeholder article likely indicating that more detailed information or a link to the relevant data would typically follow.
Wells Fargo Maintains ATyr Pharma(ATYR.US) With Hold Rating, Maintains Target Price $1
Wells Fargo analyst Derek Archila has reiterated a Hold rating for aTyr Pharma (ATYR.US) and maintained a target price of $1. According to TipRanks, Archila has a 53.7% success rate and an average return of 20.1% over the past year. This information is intended for informational purposes only and is not an investment recommendation.
aTyr Pharma stock tumbles on new Phase 3 trial plans
aTyr Pharma's stock fell 15% after the company announced plans for a new Phase 3 study of efzofitimod for pulmonary sarcoidosis. The study will evaluate the drug's effectiveness in patients with chronic, symptomatic pulmonary sarcoidosis and restrictive lung disease, incorporating feedback from the FDA. The global trial is expected to enroll approximately 372 patients and will increase dosing frequency compared to previous trials.
aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting
aTyr Pharma announced its path forward for efzofitimod in pulmonary sarcoidosis following an FDA Type C meeting. The company plans to submit an Investigational New Drug (IND) application in June 2026 for a new Phase 3 study, prioritizing Forced Vital Capacity (FVC) as the primary endpoint and King’s Sarcoidosis Questionnaire (KSQ)-Lung score as the key secondary endpoint. This strategy focuses on patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease, aiming to enhance treatment effects by increasing dosing frequency while maintaining safety.
aTyr Pharma Revamps Efzofitimod Path With New Phase III Sarcoidosis Trial
aTyr Pharma is moving forward with a new Phase III trial for efzofitimod, targeting pulmonary sarcoidosis patients with restrictive lung disease, following feedback from the FDA. The new trial will focus on forced vital capacity (FVC) as the primary endpoint and King’s Sarcoidosis Questionnaire (KSQ) lung score as a key secondary endpoint, after the previous EFZO-FIT study missed its primary endpoint but showed benefits in quality-of-life measures. The company aims to enroll approximately 372 patients globally and sees a significant market opportunity in the U.S. alone, while exploring financing options for the multi-billion dollar endeavor.
aTyr Pharma Announces New Phase 3 Sarcoidosis Trial
aTyr Pharma announced a new global Phase 3 trial for efzofitimod in restrictive pulmonary sarcoidosis, following FDA guidance. The redesigned 54-week study will feature more frequent dosing and will focus on improved clinical endpoints like FVC and KSQ-L scores, along with enhanced safety monitoring. This comes after the initial EFZO-FIT trial missed its primary endpoint but demonstrated safety benefits.
aTyr Pharma Provides Regulatory and Clinical Update for
aTyr Pharma announced a revised development path for its lead therapeutic candidate, efzofitimod, in pulmonary sarcoidosis following a Type C meeting with the FDA. The company plans to submit an IND in June 2026 for a new Phase 3 study, using forced vital capacity (FVC) as the primary endpoint and King’s Sarcoidosis Questionnaire (KSQ)-Lung score as the key secondary endpoint. This strategy targets patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease, incorporating FDA feedback on clinically relevant endpoints and increasing dosing frequency to enhance efficacy without compromising safety.
aTyr plans 54-week global trial for pulmonary sarcoidosis candidate efzofitimod
aTyr Pharma announced its regulatory and clinical path for efzofitimod in pulmonary sarcoidosis after an FDA Type C meeting, planning to submit an IND in June 2026 for a new global Phase 3 trial. The 54-week study will enroll approximately 372 patients, using FVC as the primary endpoint and KSQ-Lung as a key secondary endpoint, with dosing every three weeks at 5.0 mg/kg. This strategy follows feedback from the FDA and aims to build on previous trial data showing benefits in a restrictive lung disease subgroup.
FDA feedback guides aTyr Pharma (NASDAQ: ATYR) toward new Phase 3 sarcoidosis trial
aTyr Pharma (NASDAQ: ATYR) is moving forward with a new global Phase 3 trial for its lead drug efzofitimod in pulmonary sarcoidosis, following feedback from the FDA. The trial will focus on patients with chronic, symptomatic restrictive lung disease, using forced vital capacity (FVC) as the primary endpoint. The company plans to submit an Investigational New Drug (IND) application in June 2026, incorporating enhanced safety monitoring and a revised dosing regimen.
aTyr Pharma plans new phase 3 trial for pulmonary sarcoidosis drug
aTyr Pharma plans to submit an investigational new drug application in June 2026 for a new Phase 3 study of efzofitimod for pulmonary sarcoidosis. The company received FDA feedback confirming forced vital capacity and the King’s Sarcoidosis Questionnaire-Lung score as key measures. The upcoming global trial will evaluate efzofitimod's efficacy and safety in patients with moderate to severe pulmonary sarcoidosis, despite prior trial results not meeting primary endpoints.
aTyr Pharma Inc options imply 14.1% move in share price post-earnings
Options trading for aTyr Pharma (ATYR) Inc suggests a potential 14.1% fluctuation in its share price following the release of its earnings report. Call options significantly outnumber put options at a ratio of 22:1, indicating a bullish sentiment among options traders. While the implied volatility points to a 14.1% move, the median post-earnings movement for the stock over the past eight quarters has been 5.9%.
aTyr Pharma (Nasdaq:ATYR) - Stock Analysis
This Simply Wall St analysis of aTyr Pharma (ATYR) provides a comprehensive overview of the clinical-stage biotechnology company. It covers valuation, future growth, past performance, financial health, and recent news, highlighting the company's focus on therapies for fibrosis and inflammation, particularly efzofitimod for pulmonary sarcoidosis. The report also addresses significant risks such as unprofitability, volatile share price, and shareholder dilution, alongside recent insider transactions and analyst updates.
aTyr Pharma Inc expected to post a loss of 15 cents a share - Earnings Preview
aTyr Pharma Inc is projected to report a loss of 15 cents per share. This information comes from an earnings preview. The full article, sourced from Reuters, details this financial outlook for the company, identified by the stock symbol ATYR.
aTyr Pharma (ATYR) Projected to Post Earnings on Wednesday
aTyr Pharma (ATYR) is projected to report its Q1 2026 earnings before market open on Wednesday, May 6th, with analysts expecting an EPS of ($0.16). The company previously beat estimates in the last quarter. Institutional investors hold approximately 61.72% of the stock, and analysts currently have an average "Hold" rating with a target price of $25.67.
Facioscapulohumeral Muscular Dystrophy Market: Pharma Pipeline Fuels Rapid Expansion – DelveInsight | Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, Fulcrum Therapeutics
The Facioscapulohumeral Muscular Dystrophy (FSHD) market is poised for rapid expansion, driven by increasing disease prevalence and a robust pharmaceutical pipeline. Key companies like Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, and Fulcrum Therapeutics are developing novel therapies, including genetic and epigenetic approaches, with several candidates advancing through clinical trials. DelveInsight's report highlights significant market growth potential, especially with anticipated FDA approvals and the high demand for effective treatments in a disease area currently lacking approved therapies.
aTyr Pharma Inc stock (US53227K1025): Is efzofitimod's Phase 3 data the real test for pulmonary sarcoidosis upside?
aTyr Pharma Inc is at a crucial juncture with its lead candidate, efzofitimod, as Phase 3 data for pulmonary sarcoidosis is anticipated. Success in this rare lung condition, which currently lacks approved therapies, could significantly unlock market potential for the U.S.-centric biotech. Investors are closely watching for positive trial readouts and potential partnerships that could accelerate global reach and provide non-dilutive funding, though binary trial risk remains a significant consideration.
aTyr Pharma stock tanks after missing main goal in lung disease study
aTyr Pharma's stock has significantly dropped after its experimental drug, efzofitimod, failed to meet the primary endpoint in a late-stage clinical trial for patients with interstitial lung disease. Despite missing the main goal, the company stated that efzofitimod demonstrated a treatment effect and was well-tolerated. This setback has led to investor concern and a sharp decline in share value.
aTyr Pharma, Inc. (NASDAQ:ATYR) Given Average Recommendation of "Hold" by Brokerages
Seven brokerage firms have assigned an average "Hold" recommendation to aTyr Pharma, Inc. (NASDAQ:ATYR), with one analyst issuing a "sell" rating, five a "hold," and one a "buy." The average 12-month price target is $25.67. The company's stock opened at $0.85, has a market cap of $83.7 million, and recently reported Q1 EPS of ($0.14), beating estimates.
aTyr Pharma, Inc. (ATYR) Stock Analysis: Understanding the 417% Potential Upside in the Biotech Sector
aTyr Pharma, Inc. (ATYR) is a clinical-stage biotechnology company with a significant 417% potential upside according to analyst price targets. The company is focused on developing novel therapies for fibrosis and inflammation, with its lead candidate efzofitimod currently in Phase 3 clinical trials. Despite a modest market capitalization and negative financial metrics typical for a development-stage biotech, aTyr's promising pipeline and strategic collaborations make it a compelling, albeit volatile, investment opportunity.
aTyr Pharma Inc stock (US53227K1025): Is efzofitimod's pulmonary sarcoidosis data strong enough to unlock new upside?
aTyr Pharma, a clinical-stage biopharmaceutical company, is developing efzofitimod for pulmonary sarcoidosis, a rare inflammatory lung disease. The stock represents a high-risk, high-reward investment due to the late-stage trials and potential catalysts. Analysts maintain a generally positive stance, citing efzofitimod's potential for substantial upside if Phase 3 results, expected in late 2025 or early 2026, are positive.
Head-to-Head: Silo Pharma vs. aTyr Pharma
This article provides a head-to-head comparison of two small-cap biopharmaceutical companies, Silo Pharma (NASDAQ:SILO) and aTyr Pharma (NASDAQ:ATYR), for investors interested in the biotech sector. It evaluates them based on profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings, and risk. The goal is to help investors determine which stock might be a better fit for their portfolio.
ATYR Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for aTyr Pharma Inc (ATYR), indicating a "Strong Buy" consensus based on various technical indicators. It details momentum indicators like RSI and MACD, support and resistance levels, and performance relative to moving averages, offering insights for potential investors.
[ARS] aTYR PHARMA INC SEC Filing
This article announces an ARS SEC filing by aTYR PHARMA INC (ATYR) on March 26, 2026, detailing that the filing impact is low and the sentiment is neutral. It provides a link to view the PDF document on SEC EDGAR and lists recent news and SEC filings for the company. The article also includes key stock data for ATYR.
Vanguard disaggregates holdings; reports 0 shares in aTyr Pharma (ATYR)
Vanguard has filed an amended Schedule 13G for aTyr Pharma (ATYR), reporting 0 shares beneficially owned and 0% of common stock. This change is due to an internal realignment on January 12, 2026, where Vanguard's subsidiaries will now report beneficial ownership separately, as per SEC guidance. This is an administrative reclassification, not an economic disposition, and subsequent filings from Vanguard affiliates are expected to show their individual holdings.
aTyr Pharma, Inc. (NASDAQ:ATYR) Given Average Recommendation of "Hold" by Analysts
aTyr Pharma, Inc. (NASDAQ:ATYR) has received a consensus "Hold" recommendation from seven analysts, with an average 12-month price target of $25.67. The clinical-stage biotech, focused on rare disease therapies, recently reported better-than-expected EPS and analysts predict -0.91 EPS for the current fiscal year. Institutional investors hold a significant 61.72% of the company's stock, which recently traded down 4.6% at $0.79.
aTyr Pharma (NASDAQ:ATYR) Upgraded at Wall Street Zen
Wall Street Zen has upgraded aTyr Pharma (NASDAQ:ATYR) from a "sell" to a "hold" rating, contributing to a consensus "Hold" rating among analysts with an average price target of $25.67. The company's stock currently trades around $0.85, and it recently reported a quarterly EPS beat of ($0.14) against an estimated ($0.18). Institutional investors, including several hedge funds, now own approximately 61.72% of the company's shares.
aTyr Pharma Inc Stock (ISIN: US53227K1025) Faces Uncertainty Amid Delisting Risk and Pipeline Focus
aTyr Pharma Inc (NASDAQ: LIFE) is facing delisting risks while investors focus on its lead candidate, efzofitimod, which is in Phase III trials for pulmonary sarcoidosis. The company, which specializes in tRNA synthetase biology in immunology, maintains a micro-cap valuation of $131 million and is navigating financial hurdles, including a burn rate that projects cash into 2027. Despite financial pressures, aTyr's pipeline and strategic partnerships, like the one with Kyorin Pharmaceutical, offer potential for future growth if efzofitimod achieves clinical success.
